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Purpose: Dupuytren’s disease (DD) is a common fibrotic condition of the palmar fascia,
leading to deposition of collagen-rich cords and finger contractions. The metzincin super-
family contains key enzymes in the turnover of collagen and other extracellular matrix
macromolecules. A number of broad-spectrum matrix metalloproteinase inhibitors, used in
cancer clinical trials, caused side effects of DD-like contractures. We tested the hypothesis
that changes in the expression of specific metalloproteinases underlie or contribute to the
fibrosis and contracture seen in DD.
Methods: We collected tissue from patients with DD and used normal palmar fascia as a
control. We profiled the expression of the entire matrix metalloproteinase (MMP), tissue
inhibitor of metalloproteinases (TIMP), and a disintegrin and metalloproteinase domain with
thrombospondin motif (ADAMTS) gene families in these tissues using real-time reverse-
transcription polymerase chain reaction.
Results: A number of metalloproteinases and inhibitors are regulated in DD. The expression
of 3 key collagenases, MMP1, MMP13, and MMP14 is increased significantly in the DD
nodule, as is the expression of the collagen biosynthetic enzyme ADAMTS14. The expression
of MMP7, an enzyme with broad substrate specificity, is increased in the DD nodule and
remains equally expressed in the DD cord. TIMP1 expression is increased significantly in DD
nodule compared with normal palmar fascia.
Conclusions: This study measured the expression of all MMP, ADAMTS, and TIMP genes in
DD. Contraction and fibrosis may result from: (1) increased collagen biosynthesis mediated
by increased ADAMTS-14; (2) an increased level of TIMP-1 blocking MMP-1– and MMP-
13–mediated collagenolysis; and (3) contraction enabled by MMP-14–mediated pericellular
collagenolysis (and potentially MMP-7), which may escape inhibition by TIMP-1. The
complete expression profile will provide a knowledge-based approach to novel therapeutics
targeting these genes. (J Hand Surg 2007;32A:343–351. Copyright © 2007 by the American
Society for Surgery of the Hand.)
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aupuytren’s disease (DD) is a common con-
dition with 4% to 6% of Caucasian popula-
tions having evidence of disease,1 and affect-
ng up to 20% of men older than 65 years of age.2
linically it is characterized by fibrosis of the palmar
ascia; progression and potentially onset of the dis-
ase involves the formation and proliferation of myo-
broblasts. Three distinct histologic phases have aeen described,3 with a proliferative phase leading to
he development of a nodular lesion, an involutional
hase in which cells align themselves to lines of
tress, and a residual phase leaving a scar-like cord
issue. Thus, the nodules are thought to represent an
ctive phase of disease with myofibroblast prolifer-
tion, whereas the cords represent late-stage disease
nd the absence of myofibroblasts.
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344 The Journal of Hand Surgery / Vol. 32A No. 3 March 2007The matrix metalloproteinases (MMPs) are a fam-
ly of 23 enzymes in human beings that include the
nly mammalian enzymes able to degrade the colla-
en triple helix in a specific manner under physio-
ogic conditions.4 The classic collagenases are
MP-1, -8, and -13 of the human enzymes. More
ecently, MMP-2 (gelatinase A) and MMP-14 (MT1-
MP) also have been shown to make this specific
leavage, although with less catalytic efficiency.5–7
ther MMPs also have been implicated in collagen
urnover (eg, MMP-3, by virtue of its ability to
ctivate the pro-enzyme form of MMP-1).8 A related
amily of metalloproteinases, a disintegrin and met-
lloproteinase domain with thrombospondin motif
ADAMTSs), have 19 members in human beings and
lso are implicated in extracellular matrix (ECM)
etabolism. These include enzymes capable of
egrading the proteoglycan, aggrecan (at least
DAMTS-1, -4, -5, -8, -9, and -15), and 3 procollagen
-propeptidases (ADAMTS-2, -3, and -14). Many
ther members of this family are of unknown func-
ion.9 A family of 4 specific inhibitors, the tissue
nhibitors of metalloproteinases (TIMPs), have been
escribed.10 Although the ability of the 4 TIMPs to
nhibit MMPs is largely promiscuous, a number of
unctional differences have been noted; for example,
IMP-2, -3, and -4, but not TIMP-1, are effective
nhibitors of the membrane-type metalloproteinase
MT-MMP) subclass. Specificity among the TIMPs
or inhibition of the ADAMTS family of metallopro-
einases also has been described, with TIMP-3
eing a potent inhibitor of ADAMTS-4 (aggre-
anase-1) and ADAMTS-5 (aggrecanase-2).11 In
any fibrotic diseases such as those affecting the
iver, lung, and skin, MMPs (and related metallo-
roteinases) and TIMPs play an important role.
ormal ECM turnover can be viewed as a balance
etween proteinase and inhibitor activities, with
brosis coming from an imbalance away from
roteolysis.4
In the 1980s and 1990s, several small molecule
nhibitors of MMPs were involved in clinical trials
n a variety of cancers.12 The major side effect of
hese drugs was a so-called musculoskeletal syn-
rome, often referred to as musculoskeletal pain
ccompanied by tendonitis.13,14 This was dose-
nd time-dependent and reversible on treatment
iscontinuation, but did not respond well to non-
teroidal anti-inflammatory drugs or low-dose ste-
oid treatment. The clinical presentation, when re-
orted in detail, is described as frozen shoulder or
condition resembling DD.15 Both of these con- citions involve similar fibrotic mechanisms (of the
houlder joint capsule in the case of frozen shoul-
er), the laying down of a collagen-rich ECM, and
he involvement of myofibroblast-mediated con-
raction.16,17 Although DD and frozen shoulder
ave different natural histories (the former a pro-
ressive disease, the latter usually self-limiting
nd resolving in time), they may well share com-
on pathways leading to contracture.16 The MMP
nhibitors that cause the musculoskeletal syndrome
re pan-MMP inhibitors, showing an approxi-
ately nanomolar (or lower) inhibition constant
gainst many of the MMPs tested. Moreover, there
s good evidence that they also may inhibit related
etalloproteinases (eg, ADAMTSs). Indeed, the
usculoskeletal syndrome usually is ascribed to
he inhibition of nontarget metalloproteinases.
The measurement of a small subset of MMPs and
IMPs (MMP-1, -2, -9, TIMP-1 and -2) in the sera of
atients with DD, compared with patients who had
arpal tunnel release, lends some support to the tenet
hat expression of these enzymes is altered in DD.18
atients with DD had significantly higher serum
IMP-1 levels and the investigators18 suggested that
here is a systemic change in the MMP-to-TIMP ratio
hat may lead to increased collagen deposition. A
icroarray analysis of gene expression in DD and
eyronie’s disease, compared with normal palmar
ascia and tunica albuginea, respectively, showed
pregulation of MMP2 and MMP9 in diseased tis-
ue.19 A reverse-transcription polymerase chain re-
ction (PCR)–based comparison of Dupuytren’s tis-
ue with frozen shoulder or control shoulder tissues
howed expression of MMP1, MMP2, MMP9, and
IMP1 in all tissues, with MMP3 absent from DD
issue and MMP14 increased compared with shoulder
issue.20 An earlier report also showed an increased
xpression of MMP-2 and MMP-9 in Dupuytren’s
issue in response to mechanical load.21 None of
hese studies were able to look at all members of the
MP, TIMP, and related metalloproteinase gene
amilies.
From these data we proposed the hypothesis that
MPs, ADAMTSs, and TIMPs may play a key role
n the onset or progression of DD and related disor-
ers. Hence, we used a quantitative reverse-transcrip-
ion PCR methodology to profile the expression of all
embers of the MMP, ADAMTS, and TIMP fami-
ies in nodule and cord tissue from DD patients and
ompared this with normal palmar fascia taken at
arpal tunnel release.
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Johnston et al / Metalloproteinases in Dupuytren’s Disease 345aterials and Methods
issue Samples
ll surgery was performed at the Norfolk and Nor-
ich University Hospital under approval from the
ocal research ethics committee and all patients gave
nformed consent. Tissue from patients with DD was
aken at fasciectomy (n  20; age range, 42–83 y; 3
omen, 20 men). Samples were divided into regions
f nodule and cord according to gross morphology.
ormal palmar fascia was taken from patients with-
ut DD who had carpal tunnel release (n  20; age
ange, 25–84 y; 17 women, 3 men). Tissue was
issected into approximately 5-mm pieces and snap
rozen in liquid nitrogen within 15 to 30 minutes of
urgery.
NA Extraction
issue was weighed and homogenized in reagent
TRIzol; Invitrogen Paisley, UK) (1 mL/0.1 g tissue)
sing an homogenizer (UltraTurrax, IKA, Staufen,
ermany). Particulates were pelleted at 10,000 g for
0 minutes at 4°C and the supernatant was recovered.
total of 600 L chloroform was added per 1 mL
RIzol, vortexed for 15 seconds, and incubated at
oom temperature for 10 minutes. The TRIzol/chlo-
oform solution was centrifuged at 10,000 g for 15
inutes at 4°C and the aqueous layer was placed into
fresh tube. A total of 0.5  volume of 100%
thanol was added and mixed. Samples were applied
o spin columns (RNeasy Mini Kit; Qiagen, Crawley,
est Sussex, UK), centrifuged at full speed for 15
econds, and the flow through was discarded as de-
cribed by Price et al.22 Columns then were washed
nd eluted according to the manufacturer’s instruc-
ions. RNA samples were quantified using a spectro-
hotometer (NanoDrop; NanoDrop Technologies,
ilmington, DE) and stored at 80°C.
ynthesis of Complementary DNA
omplementary DNA was synthesized from 1 g of
otal RNA using reverse transcriptase (Superscript II,
nvitrogen) and random hexamers in a total volume
f 20 L according to the manufacturer’s instruc-
ions. Complementary DNA was stored at 20°C
ntil used in downstream PCR.
uantitative Real-Time
olymerase Chain Reaction
ligonucleotide primers and fluorescent-labeled
robes were designed (Primer Express 1.0 software;
pplied Biosystems, Warrington, UK). Sequencesor MMP and TIMP primers and probes were as pescribed by Nuttall et al23 and ADAMTS primers
nd probes were as described by Porter et al.24 To
ontrol against amplification of genomic DNA, prim-
rs were placed within different exons close to an
ntron/exon boundary, with the probe spanning 2
eighboring exons where possible. Basic Local
lignment Search Tool (BLAST) searches for all the
rimer and probe sequences also were conducted to
nsure gene specificity. The 18S ribosomal RNA
rRNA) gene was used as an endogenous control to
ormalize for differences in the amount of total RNA
resent in each sample; 18S rRNA primers and probe
ere purchased from Applied Biosystems.
The relative quantification of genes was per-
ormed using the ABI Prism 7700 sequence detec-
ion system (Applied Biosystems) in accordance
ith the manufacturer’s protocol. Polymerase
hain reactions contained 5 ng of reverse-tran-
cribed RNA (1 ng for 18S analyses), 50% 2X
aster Mix (Tagman 2X Master Mix, Applied
iosystems), 100 nmol/L of each primer, and 200
mol/L of probe in a total volume of 25 L.
onditions for the PCR reaction were 2 minutes at
0°C, 10 minutes at 95°C, then 40 cycles each
onsisting of 15 seconds at 95°C and 1 minute at
0°C.
The threshold cycle (CT), the cycle number at
hich the signal is detectable above the baseline, was
ransformed in 2 ways. To gain an approximate com-
arison across all genes measured, the amplification
fficiency was assumed to be identical across all
rimer sets and normalized to 18S expression using a
ransformation proportional to normalized copy num-
er (2CT), where CT is CT (target gene) - CT
18S). When comparing the expression of a single
ene across sample groups, standard curves for each
ene were generated using the complementary DNA
cDNA) from one sample and making 2-fold serial
ilutions across an appropriate range. Relative input
mounts of template cDNA then were calculated
rom CT using the standard curves; data are presented
s relative levels of messenger RNA (mRNA) nor-
alized to 18S rRNA. As a final quality control for the
urified RNA samples, only those cDNAs within1.5
T of the median value for 18S for all samples were
sed in the downstream study.
To ascertain that the amplification product was
ndeed that of the desired target gene, products
ere subcloned and sequenced. All primer and
robe sets have been shown to amplify specific
roducts from appropriate human tissue sam-
les.23,24
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346 The Journal of Hand Surgery / Vol. 32A No. 3 March 2007tatistical Analysis
nalyses were performed on 19 samples from each
roup because 1 sample in each group failed quality
ontrol as detailed previously. Differences between
he 3 groups were defined using a Kruskal-Wallis
est or pair-wise comparison using a 2-sided Mann-
hitney U test (in GraphPad Prism 4; GraphPad
oftware Inc, San Diego, CA); these nonparametric
ests make no prior assumption on the data distribu-
ion. To account for differences in age and gender,
tandardized expression data using the standard
urve method were subjected to a logarithmic trans-
ormation to approximate normalization and tested
y analysis of covariance (ANCOVA; SPSS for Win-
ows; SPSS Inc, Chicago, IL). Further analysis of
igure 1. Comparative expression of MMP genes in norm
xpression level of each gene was determined as describe
evel of 18S rRNA gene expression using CT (CT [target g
oxes, nodule. The box-and-whisker plot shows the medi
etected.
igure 2. Comparative expression of ADAMTS genes in no
xpression level of each gene was determined as describe
evel of 18S rRNA gene expression using CT (CT [target g
oxes, nodule. The box-and-whisker plot shows the medi
etected.orrelation was performed using the Spearman rank
orrelation (SPSS for Windows).
esults
xamining the overall pattern of gene expression
hown in Figures 1 to 3, a striking feature is that the
evel of TIMP gene expression is higher than that of
he proteinase genes. Broadly, the level of steady-
tate mRNA across the 3 gene families assayed is
IMP  ADAMTS  MMP. Table 1 shows the dif-
erences in gene expression between the DD nodule and
ord tissue compared with normal palmar fascia.
Although DD obviously involves the laying down
f excess collagenous matrix, this matrix is presum-
bly also remodeled and shortened during disease
lmar fascia versus cord and nodule tissue from DD. The
he Materials and Methods section and normalized to the
CT [18S]). Open boxes, normal; filled boxes, cord; dotted
d each section represents a quartile of the data. N.D., not
almar fascia versus cord and nodule tissue from DD. The
he Materials and Methods section and normalized to the
CT [18S]). Open boxes, normal; filled boxes, cord; dotted
d each section represents a quartile of the data. N.D., notal pa
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Johnston et al / Metalloproteinases in Dupuytren’s Disease 347rogression either as a consequence of tension or
ontributing to increased tension. Thus, the expres-
ion of 3 procollagen N-propeptidases, ADAMTS2,
DAMTS3, and particularly ADAMTS14, is increased
n the DD nodule, consistent with an increase in
ollagen synthesis. Conversely, the expression of
everal enzymes capable of mediating collagen
reakdown, MMP1, MMP2, MMP13, and MMP14,
lso is increased in the DD nodule compared with
ormal palmar fascia, consistent with increased colla-
en turnover. The increase of all of the earlier-described
nzymes is to some extent attenuated in the DD cord.
Comparing the DD nodule with the cord, it is clear
hat many genes that are induced in the nodule are at
east less induced in the cord, with many not signif-
cantly different in the cord compared with normal
almar fascia. The only gene whose expression is
ncreased in the DD nodule and remains increased to
similar level in the DD cord is MMP7; MMP-7 has
broad substrate specificity,25 and this may represent
continued matrix remodeling process in the DD
ord (see later).
The most significantly downregulated gene in the
D nodule is MMP3. This appears to be a recurring
heme in diseases involving matrix destruction be-
ause similar findings have been reported in osteo-
rthritic cartilage26 and degenerative tendinopathy.27
Six ADAMTS enzymes have been shown to be ag-
igure 3. Comparative expression of TIMP genes in normal
almar fascia versus cord and nodule tissue from DD. The
xpression level of each gene was determined as described in
he Materials and Methods section and normalized to the
evel of 18S rRNA gene expression using CT (CT [target
ene] - CT [18S]). Open boxes, normal; filled boxes, cord;
otted boxes, nodule. The box-and-whisker plot shows the
edian, and each section represents a quartile of the data.recanases, at least in vitro, ADAMTS-1, ADAMTS-4, tDAMTS-5, ADAMTS-8, ADAMTS-9, and
DAMTS-15. ADAMTS15 is expressed in normal
almar fascia, but not regulated in DD tissue.
DAMTS4, ADAMTS5, and ADAMTS9 all are ex-
ressed in normal palmar fascia and increased in the
D nodule, but not the cord. ADAMTS1 is expressed
obustly in normal palmar fascia and expression is
ower in the DD nodule. ADAMTS8 is undetectable
n most tissue samples.
Of the TIMPs, TIMP1 expression is increased in
he DD nodule, but TIMP2, TIMP3, and TIMP4 all
re expressed at lower levels in the DD nodule than
n normal palmar fascia.
Analysis of covariance showed that there is a
elationship between the patient’s age and the level
f gene expression for MMP3, MMP16, MMP17,
MP25, TIMP1, TIMP2, ADAMTS1, ADAMTS5,
nd ADAMTS18. Analysis of covariance also showed
weak relationship between gender and expression
f MMP16, TIMP2, ADAMTS3, and ADAMTS5. The
tatistically significant differences in gene expression
or these genes between groups (detailed previously),
owever, are paralleled in this analysis in all
ases apart from ADAMTS18. The expression of
DAMTS18 shows no statistical difference between
roups under ANCOVA analysis but shows weak
ignificance when analyzed by either Kruskal-Wallis or
n pair-wise analysis using the Mann-Whitney U test.
or the expression of MMP3, TIMP1, and TIMP2, there
s a strong correlation with age in normal palmar fascia
the former 2 decreasing with age, the latter increasing)
hat is lost in DD tissues. This shows that regulatory
echanisms for these genes are aberrant in disease.
able 2 shows a Spearman rank correlation analysis
or the 9 genes showing an effect of age in ANCOVA.
igure 4 shows the correlation of MMP3 expression
ith age in the normal palmar fascia.
iscussion
n screens of gene expression the need to account for
ultiple testing in the statistical analyses is problem-
tic. The Bonferroni correction is often conservative,
emoving type I error (false positive) at the expense
f type II error (false negative). This would limit the
tility of gene expression studies in which the valid-
ty of any multiple testing procedure has yet to be
scertained.28,29 In Table 1, we have not applied any
orrection for multiple testing, although at the 5%
ignificance level (p  .05) a false-positive rate of 1
n 20 would be expected.
Of prime importance to the phenotypic outcome of
hese changes in gene expression is the final balance
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m
o
c
m
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348 The Journal of Hand Surgery / Vol. 32A No. 3 March 2007f proteinase versus inhibitor. Although this is im-
ossible to ascertain from a study at the steady-state
RNA level such as this, it is clear that TIMP1 is the
Table 1. Comparison of Gene Expression Between
From DD
Gene
Normal versus nodule
(, higher in nodule)
MMP1  .0009
MMP2  .0001
MMP3 - .0001
MMP7  .0001
MMP8 NS
MMP9 NS
MMP10 NS
MMP11  .0001
MMP12 NS
MMP13  .0001
MMP14  .0001
MMP15  .0144
MMP16  .0001
MMP17  .0001
MMP19  .0001
MMP20 ND
MMP21  .0071
MMP23 NS
MMP24 NS
MMP25 NS
MMP26 ND
MMP27 - .0003
MMP28 NS
ADAMTS1 - .011
ADAMTS2  .0012
ADAMTS3  .0034
ADAMTS4  .0024
ADAMTS5  .0066
ADAMTS6 - .0043
ADAMTS7 NS
ADAMTS8 - .0056
ADAMTS9  .0037
ADAMTS10 NS
ADAMTS12  .0001
ADAMTS13 NS
ADAMTS14  .0001
ADAMTS15 NS
ADAMTS16  .0223
ADAMTS17 NS
ADAMTS18  .036
ADAMTS19 - .0056
ADAMTS20 - .0034
TIMP1  .0008
TIMP2 - .0115
TIMP3 - .004
TIMP4 - .004
Statistical analysis was performed pair-wise using the Mann-Whitn
NS, not significant; ND, not detected.nly TIMP whose expression is increased signifi- nantly in the DD nodule compared with normal pal-
ar fascia. Indeed, TIMP2, TIMP3, and TIMP4 all
re reduced in the DD nodule. Thus, in the DD
al Palmar Fascia, Cord, and Nodule Tissue
 p value
Normal versus cord
(, higher in cord)
Nodule versus cord
(, higher in cord)
NS NS
.0043 - .0043
.0002  .0091
.0001 NS
NS  .044
NS NS
NS NS
.0001 - .004
NS NS
.0003 - .0012
NS – .0061
NS - .0098
.036 – .004
NS - .0001
NS - .0028
ND ND
NS NS
NS NS
NS NS
NS NS
ND ND
NS  .002
NS - .04
NS  .0043
NS - .012
.018 NS
NS - .0005
NS - .017
NS  .04
NS NS
NS  .0043
NS NS
NS NS
.0028 - .002
NS NS
NS - .0002
NS  .036
NS - .0024
NS NS
.0144 NS
NS  .021
NS  .0031
NS - .028
NS  .0005
NS NS
NS  .03
est.Norm

-







ey U todule, the situation may be similar to that described
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Johnston et al / Metalloproteinases in Dupuytren’s Disease 349n liver fibrosis, in which the potential for matrix
egradation is present, even in advanced disease, but
s prevented by TIMP expression.30 Of potential im-
ortance here is the fact that TIMP-1 is a poor
nhibitor of MMP-14, MMP-15, MMP-16, and
MP-24.10 Because expression of MMP14 and
MP16 is significantly increased in the DD nodule,
hese proteinases might escape inhibition from
IMP-1. This also may provide a mechanism for
ollagen remodeling, particularly in the pericellular
nvironment (by MMP-14, a membrane-bound en-
yme) during contraction in the presence of TIMP-1.
imilarly, MMP-7 (whose expression is increased
qually in both the DD nodule and the cord), lacks a
-terminal hemopexin-like domain that is common
o most MMPs, decreasing its affinity for at least
IMP-1,31 and potentially resisting inhibition in pa-
hology.
Several studies have compared the contractile prop-
rties of Dupuytren’s cord- or nodule-derived fibro-
lasts with control cultures.32–35 Results varied
epending on the model of contraction used, but
he consensus appears to be that Dupuytren’s fi-
roblasts can generate significantly increased con-
ractile force compared with control cells, with
odule-derived cells showing greatest contraction.
n such models, broad-spectrum synthetic MMP
nhibitors have been shown to inhibit contrac-
ion,36,37 and this is paralleled by the inhibition of
ound contraction in a mouse model of skin
ound healing.38 This latter study also reported a
ecrease in -smooth muscle actin expression in
he presence of the MMP inhibitor. This blockade
Table 2. Correlation of Gene Expression With
Age in Normal Palmar Fascia, Cord, or Nodule
Tissue From DD
Gene
p value (r value)
Cord Nodule Normal
MMP3 .318 .273 .001 (.774)
MMP16 .204 .307 .063 (.435)
MMP17 .322 .024 (.516) .616
MMP25 .323 .358 .115
TIMP1 .632 .557 .012 (.565)
TIMP2 .280 .416 .013 (.558)
ADAMTS1 .051 (.454) .263 .473
ADAMTS5 .627 .011 (.567) .743
ADAMTS18 .022 (.523) .468 .348
Genes shown are those identified by ANCOVA. Statistical anal-
ysis was performed using the Spearman rank correlation. The
Spearman r value is shown where correlation is significant (pos-
itive value indicates an increase in expression with age, negative
value indicates a decrease in expression with age).f contraction is difficult to dovetail with the re-
orted side effects of some of these MMP inhibi-
ors in clinical trials in which Duputyren’s-like
ontracture and frozen shoulder were observed13–15;
owever, this may reflect the fact that culture models
f collagen lattice contraction only represent a single
acet of a more complex disease process. Again,
rawing on the analogy with liver fibrosis, a treat-
ent that downregulates TIMPs but increases the
ctivity of MMPs may be an appropriate therapy for
D.30 One such possibility is relaxin, an insulin-like
rowth factor hormone reported to decrease collagen
xpression, increase MMP, and decrease TIMP ex-
ression in a variety of in vitro and in vivo mod-
ls.39–42
It also may be possible to target collagen biosyn-
hesis via blockade of ADAMTS-14. Functional
verlap between the 3 ADAMTS procollagen-N-
ropeptidases (ADAMTS-2, -3, and -14) provides
he potential to inhibit ADAMTS-14 without disrup-
ion of global collagen synthesis,43 but this may be
ufficient to slow or halt collagen deposition in DD.
The current study examines the expression of the
ntire MMP, ADAMTS, and TIMP families in DD.
hese enzymes and inhibitors have critical roles in
xtracellular matrix homeostasis, which is clearly
ysregulated in DD. These data will allow future
ork to focus on the function of specific metallopro-
einases in the disease process.
eceived for publication October 25, 2006; accepted in revised form
ecember 15, 2006.
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